Latest Glioma Stories
Results Presented at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology MIAMI, Nov.
Data Presented at the 19th Annual Society for Neuro-Oncology Meeting Demonstrate VAL-083 Superiority to Temozolomide in Key Preclinical Models VANCOUVER, British Columbia, MENLO PARK, Calif.,
Data presented today as a late-breaking abstract at the Society for Neuro-Oncology 2014 Annual Meeting in Miami demonstrated the EF-14 trial met its primary endpoint of progression-free survival and
- Data include results from a Phase 1 study of ABT-414 as monotherapy and in combination with radiation and/or chemotherapy in patients with newly diagnosed and recurrent/unresectable glioblastoma
VAL-083 Anti-tumor Activity Is Consistently Superior to Temozolomide in Preclinical Models of Glioblastoma VANCOUVER, British Columbia, MENLO PARK, Calif., and MIAMI, Nov.
Interim analysis of the pivotal phase III trial of Tumor Treating Fields in newly diagnosed glioblastoma (EF-14) will be presented as a late-breaking oral presentation ST.
HEIDELBERG, Germany, Oct.
HOUSTON, Oct. 24, 2014 /PRNewswire/ -- Burzynski Research Institute, Inc. (BRI) announced today that the U.S.
- The abrogation of a law by a higher authority; annulment.